P282 Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn’s disease

• Published in: Journal of Crohn's and colitis 2019-01, Vol.13 (Supplement_1), p.S239-S240
• Main Authors: Mortensen, J H, Karsdal, M A, Grønbæk, H, Hvas, C L, Dige, A, Manon-Jensen, T
• Format: Article
• Language: English
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjy222.406

Abstract Background In inflammatory bowel diseases (IBD), up to 40% of patients do not respond to biologic treatment, eg, anti-TNFα antibodies. A personalised medicine approach may facilitate the best possible treatment option for IBD patients. Currently, no biomarkers have sufficient sensitivity to separate responders from non-responders within the first weeks of anti-TNFα therapy, which limits the personalised medicine approach for IBD patients. We investigated serum biomarkers that reflect basement membrane degradation (C4M: MMP mediated degradation of type IV collagen) and citrullinated vimentin (VICM: activated macrophages), and their ability to predict response to anti-TNFα treatment in Crohn’s disease. Methods This was a single-centre cohort study. We measured clinical response to adalimumab at Week 8 after treatment induction in 22 patients with Crohn’s disease, using the Harvey–Bradshaw Index (HBI). Response was defined as clinical remission (HBI